Show simple item record

dc.contributor.authorFrere, M
dc.contributor.authorTepper, J
dc.date.accessioned2016-11-01T12:18:39Z
dc.date.available2016-11-01T12:18:39Z
dc.date.issued2016-09
dc.identifier.urihttp://hdl.handle.net/10147/620895
dc.descriptionMajor Depressive Disorder (MDD) is a debilitating mental health condition which accounts for a significant portion of worldwide disability. Historically, the suggested pharmacotherapy to treat MDD have been monoaminergic-acting antidepressants, such as SSRIs or SNRIs. These drugs can provide relief, but often take weeks to noticeably improve depressive symptoms and are not always effective, leading to a condition known as Treatment-Resistant Depression (TRD). It is believed that 50% MDD sufferers in Ireland suffer from TRD, and thus the development of improved pharmacotherapies is necessary. One emerging therapy is low dose, intravenous (R-S)-Ketamine (ketamine). While the molecular basis of ketamine’s therapeutic effect has not been fully determined, it has shown to effectively and swiftly mitigate the symptoms of TRD. Barriers do exist preventing the legal prescription of ketamine, including its questionable safety profile and risk of inducing dependence. Despite this, ketamine remains a promising pharmacotherapy for TRD and further investigation is required.en
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.relation.urlhttp://imj.ie/this-months-imj-september-2016-vol-109-number-8/en
dc.subjectDEPRESSIONen
dc.subjectDRUG THERAPYen
dc.titleKetamine: Future Treatment For Unresponsive Depression?en
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen


Files in this item

Thumbnail
Name:
art7.html
Size:
31.64Kb
Format:
HTML
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record